NeuroSense Therapeutics Announces Data From Its Phase 2 RoAD Trial Of PrimeC In Alzheimer's Disease Demonstrates Multiple Protein Biomarker Changes; Distinctive Changes Also Seen In Levels Of Other Major Neurodegenerative Disease Misfolding Proteins

Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and revenue of $4.7 billion, leading to a 4.7% jump in pre-market trading. Other top gainers include C3is, INLIF, and Polar Power. FIEE and KIDZ were among the top losers.

NeuroSense Intends To Proceed With Filing Of NDS To Health Canada For PrimeC For Treatment Of Amyotrophic Lateral Sclerosis, Following Constructive Pre-NDS Meeting

The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway

NeuroSense Therapeutics Announces Its Phase 2B PARADIGM Study Of PrimeC In Amyotrophic Lateral Sclerosis Has Met Its Primary Efficacy Endpoint